Literature DB >> 10908002

The CSAT methamphetamine treatment program: research design accommodations for "real world" application.

A Huber1, R H Lord, V Gulati, P Marinelli-Casey, R Rawson, W Ling.   

Abstract

The Methamphetamine Treatment Program (MTP), funded by the Center for Substance Abuse Treatment, has the objectives of implementing the Matrix outpatient model and evaluating that model in comparison to the existing community "treatments as usual." Seven organizations in three western states (California, Montana, and Hawaii) were selected to participate in this randomized, controlled, multisite project in what constitutes the largest trial to date of treatment for methamphetamine (MA) dependence. One hundred fifty MA-dependent patients recruited at each site are randomly assigned to receive either the Matrix model, a manualized program of intensive outpatient treatment, or the site's standard treatment, "treatment as usual." Participants are evaluated at admission, weekly during treatment, at the time of scheduled discharge, and at six and 12 months after admission. Dependent measures assess changes in drug use, HIV risk behaviors, quality of life, and patient satisfaction. Cost analyses to quantify treatment costs and determine the association between costs and clinical outcomes will be conducted. A number of adjustments in the original study design have been necessitated by the realities of community sites' strengths and limitations. Experiences from this multisite project will also provide a model for other efforts to transfer research-based treatments into community settings. This article describes the main aims of the project, the background and rationale for the study design, a brief description of the research plan, and methods implemented to protect the integrity of the science.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908002     DOI: 10.1080/02791072.2000.10400223

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  8 in total

1.  Strategies to encourage adoption in multisite clinical trials.

Authors:  Joseph Guydish; Barbara Tajima; Sarah Turcotte Manser; Martha Jessup
Journal:  J Subst Abuse Treat       Date:  2006-11-22

2.  Multi-level assessment protocol (MAP) for adoption in multi-site clinical trials.

Authors:  J Guydish; S T Manser; M Jessup; B Tajima; C Sears; T Montini
Journal:  J Drug Issues       Date:  2005-07-01

3.  Quality of life among treatment seeking methamphetamine-dependent individuals.

Authors:  Rachel Gonzales; Alfonso Ang; Deborah C Glik; Richard A Rawson; Stella Lee; Martin Y Iguchi
Journal:  Am J Addict       Date:  2011-05-31

4.  Soda Consumption Among Methamphetamine Users in the USA: Impact on Oral Health.

Authors:  Debra A Murphy; Lauren Harrell; Rachel Fintzy; Steven Vitero; Alexis Gutierrez; Vivek Shetty
Journal:  Oral Health Prev Dent       Date:  2016       Impact factor: 1.256

5.  The relationship between methamphetamine use and increased dental disease.

Authors:  Vivek Shetty; Larissa J Mooney; Corwin M Zigler; Thomas R Belin; Debra Murphy; Richard Rawson
Journal:  J Am Dent Assoc       Date:  2010-03       Impact factor: 3.634

6.  Implementation and acceptability of Mindful Awareness in Body-oriented Therapy in women's substance use disorder treatment.

Authors:  Cynthia J Price; Elizabeth A Wells; Dennis M Donovan; Marissa Brooks
Journal:  J Altern Complement Med       Date:  2012-04-23       Impact factor: 2.579

7.  Process-of-care measures as predictors of client outcome among a methamphetamine-dependent sample at 12- and 36-month follow-ups.

Authors:  Richard A Rawson; Rachel Gonzales; Lisa Greenwell; Mady Chalk
Journal:  J Psychoactive Drugs       Date:  2012 Sep-Oct

8.  How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: Craving and ongoing methamphetamine use.

Authors:  Gantt P Galloway; Edward G Singleton
Journal:  Subst Abuse       Date:  2009-08-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.